German company Grünenthal has acquired US-based Valinor Pharma along with its product Movantik (naloxegol) for approximately $250 million. Movantik is indicated for the oral treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. Gross sales from the drug in the United States (US) reached over $200 million in 2023. "As a pain […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!